EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interstitial Lung Disease in the United States: CDC Mortality Trends (1999–2024)

Palak Grover, Rahul Jain, Gurleen Kaur, Bipneet Singh iD

Advances in Respiratory Medicine · 24.07.2026 · 94 (4) · 51

DOI: 10.3390/arm94040051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Respiratory Medicine, online erschienen am 24.07.2026. Verfasst von Palak Grover und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Henry Ford Jackson Hospital, Jackson, MI 49201, USA. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interstitial lung diseases (ILDs) comprise a heterogeneous group of pulmonary disorders associated with substantial morbidity and mortality. We examined mortality attributed to selected J84-coded ILDs in the United States from 1999 to 2024 using CDC WONDER underlying-cause-of-death data. Age-adjusted mortality rates (AAMRs) per 100,000 population were standardized to the 2000 U.S. population and stratified by sex and race. Joinpoint regression was used to identify changes in temporal slope and estimate annual percent change (APC), average annual percent change (AAPC), 95% confidence intervals (CIs), and p-values. After the removal of overlapping years between the CDC WONDER database series, 444,573 unique deaths occurred. Annual deaths increased from 11,358 in 1999 to 22,849 in 2024, while AAMR increased from 4.2 to 5.1 per 100,000. Overall, AAMR increased during 1999–2004 (APC 2.32%, 95% CI 1.39–3.26; p < 0.001) and more slowly during 2004–2024 (APC 0.36%, 95% CI 0.16–0.56; p = 0.001), with an overall AAPC of 0.75% (95% CI 0.60–0.90; p < 0.001). Male AAMRs remained higher than female AAMRs, while race-specific trends were heterogeneous. No temporal reduction in population mortality coincided with the introduction of antifibrotic therapies; however, this ecological analysis cannot evaluate treatment effectiveness or individual treatment exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialHumansUnited StatesFemaleMaleCenters for Disease Control and Prevention, U.S.AgedMiddle AgedMortalityCause of Death

Stichwörter der Autor:innen

idiopathic pulmonary fibrosisinterstitial lung diseasesystemic sclerosis

Autor:innen und Institutionen

  • Department of Internal Medicine, Henry Ford Jackson Hospital, Jackson, MI 49201, USA.
  • Department of Internal Medicine, Sri Manakula Vinayagar Medical College, Puducherry 605107, India.
  • Department of Internal Medicine, Government Medical College, Amritsar 143001, India.
  • Department of Gastroenterology, University of Kentucky, Lexington, KY 40506, USA.

ORCID-Profile: Bipneet Singh

Zitieren

APA

Grover, P., Jain, R., Kaur, G., & Singh, B. (2026). Interstitial Lung Disease in the United States: CDC Mortality Trends (1999–2024). Advances in Respiratory Medicine, 94(4), 51. https://doi.org/10.3390/arm94040051

Vancouver

Grover P, Jain R, Kaur G, Singh B. Interstitial Lung Disease in the United States: CDC Mortality Trends (1999–2024). Advances in Respiratory Medicine. 2026;94(4):51. doi:10.3390/arm94040051

BibTeX
@article{Grover2026,
  author = {Grover, Palak and Jain, Rahul and Kaur, Gurleen and Singh, Bipneet},
  title = {Interstitial Lung Disease in the United States: CDC Mortality Trends (1999–2024)},
  journal = {Advances in Respiratory Medicine},
  year = {2026},
  volume = {94},
  number = {4},
  pages = {51},
  doi = {10.3390/arm94040051}
}
Kostenlos starten →